Finance

Lists
Q3 2026 earnings • in 1 day
See details
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$29.20
+4.14%
(+1.16) 1D
$29.20
0.00% (0.00)
After hours
Closed: Nov 3, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMLX...
Open
$28.52
High
$29.46
Low
$28.21
Mkt. cap
3.66B
Avg. vol.
1.30M
Volume
1.20M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.09
Shares outstanding
125.51M
No. of employees
136
Open
$28.52
High
$29.46
Low
$28.21
Mkt. cap
3.66B
Avg. vol.
1.30M
Volume
1.20M
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.09
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc
CEO-
Employees136
Founded2013
Headquarters-
SectorPharmaceutical industry
Industry-
Websiteamylyx.com
Analyst ratings
Based on 9 analysts giving stock ratings to AMLX in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for AMLX in the last 3 months.
Highest
Current $29.20
$57.00 (+95.21%)
Average
$46.13 (+57.98%)
Lowest
$38.00 (+30.14%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$38.00
+30.1%
10/29/2026
Geoff Meacham
Citi
Buy
Maintained
$39.00
+33.6%
10/16/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
$45.00
+54.1%
10/01/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$57.00
+95.2%
08/26/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$44.00
+50.7%
08/22/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/18/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$39.00
+33.6%
08/18/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$52.00
+78.1%
08/18/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$55.00
+88.4%
08/20/2026
Dina Ramadane
Bank of America Securities
Buy
Reiterated
$30.00
+2.7%
08/07/2026
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$34.00
+16.4%
07/01/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$23.00
-21.2%
06/18/2026
Next call in 31:41:37
Thu, Nov 5, 3:00 PM
Fiscal period
Q3 2026
- / -$0.37
Revenue / Est. (USD)
- / 41.60K
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
-
-
Operating expense
-
-
-
-
Total operating expenses
-
-
-
-
Operating income
-
-
-
-
Other non operating income
-
-
-
-
EBT including unusual items
-
-
-
-
EBT excluding unusual items
-
-
-
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-
-
-
-
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps